Company profile for Everads Therapy

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Everads Therapy is an early-stage life sciences company developing the next generation of retinal treatment delivery technologies. With the goal of overcoming significant challenges in current treatment methodologies for retinal and macular diseases, Everads' delivery system offers the promise of improving the efficacy and safety of existing and potential drug therapies. Established in 2017, Everads Therapy operates within the...
Everads Therapy is an early-stage life sciences company developing the next generation of retinal treatment delivery technologies. With the goal of overcoming significant challenges in current treatment methodologies for retinal and macular diseases, Everads' delivery system offers the promise of improving the efficacy and safety of existing and potential drug therapies. Established in 2017, Everads Therapy operates within the RAD Biomed incubator in Tel Aviv, Israel. Its underlying technologies have been licensed from the Sheba Medical Center at Tel Hashomer.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
Migdalei Orr,. Building A 27 Habarzel st. 5ft floor, Migdaly Or, Building A, i...
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/everads-announces-two-oral-presentations-at-asrs-2025-including-full-clinical-trial-results-with-its-novel-suprachoroidal-injector-302517682.html

PR NEWSWIRE
30 Jul 2025

https://www.prnewswire.com/news-releases/everads-announces-five-abstracts-accepted-for-presentation-at-arvo-2025-including-first-in-human-results-using-its-novel-suprachoroidal-injector-302444028.html

PR NEWSWIRE
01 May 2025

https://www.prnewswire.com/news-releases/everads-enters-license-agreement-with-kriya-for-development-of-ocular-gene-therapy-candidates-using-everads-suprachoroidal-delivery-technology-301940335.html

PR NEWSWIRE
27 Sep 2023

https://www.prnewswire.com/news-releases/vivavision-and-everads-collaborate-to-develop-durable-and-effective-therapies-for-retinal-diseases-301715314.html

PR NEWSWIRE
06 Jan 2023

https://www.prnewswire.com/news-releases/everads-enters-into-collaboration-to-evaluate-its-suprachoroidal-delivery-technology-with-a-clinical-stage-gene-therapy-company-301323334.html

PR NEWSWIRE
30 Jun 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty